tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SRRK Stock Latest News

Scholar Rock assumed with a Buy at Jefferies
The FlyScholar Rock assumed with a Buy at Jefferies
18d ago
SRRK
Scholar Rock publishes SAPPHIRE trial data in The Lancet
PremiumThe Fly
Scholar Rock publishes SAPPHIRE trial data in The Lancet
25d ago
SRRK
Positive Outlook on Scholar Rock Holdings Due to Innovative Therapies and Strategic Advancements
PremiumRatings
Positive Outlook on Scholar Rock Holdings Due to Innovative Therapies and Strategic Advancements
29d ago
SRRK
Scholar Rock’s Optimistic Earnings Call Highlights Progress
PremiumCompany Announcements
Scholar Rock’s Optimistic Earnings Call Highlights Progress
1M ago
SRRK
Scholar Rock Reports Q2 2025 Progress and Financials
PremiumCompany Announcements
Scholar Rock Reports Q2 2025 Progress and Financials
1M ago
SRRK
Optimistic Buy Rating for Scholar Rock Amid Apitegromab’s Promising FDA Review and Market Expansion Potential
PremiumRatingsOptimistic Buy Rating for Scholar Rock Amid Apitegromab’s Promising FDA Review and Market Expansion Potential
1M ago
SRRK
Scholar Rock reports Q2 EPS (98c), consensus (67c)
Premium
The Fly
Scholar Rock reports Q2 EPS (98c), consensus (67c)
1M ago
SRRK
Scholar Rock’s Apitegromab Receives FDA Priority Review
Premium
Company Announcements
Scholar Rock’s Apitegromab Receives FDA Priority Review
1M ago
8K
SRRK
Scholar Rock assumed with a Strong Buy at Raymond James
PremiumThe Fly
Scholar Rock assumed with a Strong Buy at Raymond James
1M ago
SRRK
Scholar Rock initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Scholar Rock initiated with an Overweight at Cantor Fitzgerald
2M ago
SRRK
JPMorgan adds Scholar Rock to Focus List, ‘Positive Catalyst Watch’
PremiumThe Fly
JPMorgan adds Scholar Rock to Focus List, ‘Positive Catalyst Watch’
2M ago
SRRK
GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
PremiumThe Fly
GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
3M ago
HD
KR
Buy Rating for Scholar Rock Holding: Promising Clinical Advancements and Strategic Focus Highlighted by Phase 2 EMBRAZE Trial Results
PremiumRatingsBuy Rating for Scholar Rock Holding: Promising Clinical Advancements and Strategic Focus Highlighted by Phase 2 EMBRAZE Trial Results
3M ago
SRRK
Strategic Focus on Neuromuscular Treatments and Promising Study Results Justify Buy Rating for Scholar Rock
Premium
Ratings
Strategic Focus on Neuromuscular Treatments and Promising Study Results Justify Buy Rating for Scholar Rock
3M ago
SRRK
Scholar Rock’s Strategic Shift and Promising Advancements Drive Buy Rating
Premium
Ratings
Scholar Rock’s Strategic Shift and Promising Advancements Drive Buy Rating
3M ago
SRRK
Morning Movers: Circle rises following regulatory framework for stablecoins
PremiumThe Fly
Morning Movers: Circle rises following regulatory framework for stablecoins
3M ago
CC
ACB
Scholar Rock up 14% at $35.41 after disclosing results from EMBRAZE trial
PremiumThe Fly
Scholar Rock up 14% at $35.41 after disclosing results from EMBRAZE trial
3M ago
SRRK
Scholar Rock Announces Positive Phase 2 Trial Results
PremiumCompany Announcements
Scholar Rock Announces Positive Phase 2 Trial Results
3M ago
8K
SRRK
Scholar Rock announces results from EMBRAZE trial
PremiumThe Fly
Scholar Rock announces results from EMBRAZE trial
3M ago
SRRK
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
PremiumThe FlyJefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
3M ago
LLY
MRK
Positive Outlook on Scholar Rock’s Apitegromab Driven by Promising Trial Results and Potential in Obesity and SMA Treatment
Premium
Ratings
Positive Outlook on Scholar Rock’s Apitegromab Driven by Promising Trial Results and Potential in Obesity and SMA Treatment
3M ago
SRRK
Promising Potential in Scholar Rock’s Obesity and SMA Programs Drives Buy Rating
Premium
Ratings
Promising Potential in Scholar Rock’s Obesity and SMA Programs Drives Buy Rating
3M ago
SRRK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >